Calcium propane-2-sulfinate dihydrate
US-9757367-B2 · Sep 12, 2017 · US
Processes of making and crystalline forms of a mdm2 inhibitor
US2016289243A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016289243-A1 |
| Application number | US-201615175805-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 7, 2016 |
| Priority date | Jun 10, 2013 |
| Publication date | Oct 6, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
First claim
Opening claim text (preview).
1 .- 6 . (canceled) 7 . The compound 8 . The compound 9 . Crystalline 10 . Crystalline characterized by a powder X-ray diffraction pattern comprising peaks at diffraction angle 2 theta degrees at approximately 8.7, 18.5, 22.6 and 26.6. 11 . Crystalline in accordance with claim 10 having the X-ray diffraction pattern substantially shown in FIG. 3 . 12 .- 38 . (canceled)
Assignees
Inventors
Classifications
containing only one sulfo group · CPC title
- C07C309/35Primary
Naphthalene sulfonic acids · CPC title
Crystalline forms, e.g. polymorphs · CPC title
- C07D211/94Primary
Oxygen atom, e.g. piperidine N-oxide · CPC title
- A61K31/451Primary
having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016289243A1 cover?
- The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07C309/35. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Oct 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).